NOUBAR AFEYAN Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for NOUBAR AFEYAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of NOUBAR AFEYAN. NOUBAR AFEYAN is Director in AGENUS INC ($AGEN) and Director in BG Medicine, Inc. ($BGMD) and Director in Seres Therapeutics, Inc. ($MCRB) and Director in Moderna, Inc. ($MRNA) and Director in Evelo Biosciences, Inc. ($EVLO) and Director in Rubius Therapeutics, Inc. ($RUBY).
Latest Insider Trading Transactions of NOUBAR AFEYAN
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AGEN, BGMD, EVLO, MRNA, RUBY, MCRB
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 13 2021 | RUBY | Rubius Therapeutic ... | AFEYAN NOUBAR | Director | Option Exercise | A | 23.25 | 25,000 | 581,250 | 25,000 | |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 121.07 | 4,888 | 591,810 | 9,116,657 | 9.1 M to 9.1 M (-0.05 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 123.44 | 1,000 | 123,440 | 9,121,545 | 9.1 M to 9.1 M (-0.01 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 123.08 | 31,943 | 3,931,538 | 9,122,545 | 9.2 M to 9.1 M (-0.35 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 121.71 | 14,379 | 1,750,038 | 9,154,488 | 9.2 M to 9.2 M (-0.16 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 120.76 | 225,732 | 27,259,283 | 9,168,867 | 9.4 M to 9.2 M (-2.40 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 119.81 | 344,542 | 41,278,061 | 9,394,599 | 9.7 M to 9.4 M (-3.54 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 118.90 | 611,922 | 72,758,505 | 9,739,141 | 10.4 M to 9.7 M (-5.91 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 118.04 | 883,277 | 104,265,815 | 10,351,063 | 11.2 M to 10.4 M (-7.86 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 131.30 | 558 | 73,265 | 11,234,340 | 11.2 M to 11.2 M (0.00 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 130.56 | 6,610 | 862,994 | 11,234,898 | 11.2 M to 11.2 M (-0.06 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 129.54 | 83,242 | 10,783,377 | 11,241,508 | 11.3 M to 11.2 M (-0.74 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 128.74 | 123,374 | 15,883,527 | 11,324,750 | 11.4 M to 11.3 M (-1.08 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 127.47 | 46,872 | 5,974,788 | 11,448,124 | 11.5 M to 11.4 M (-0.41 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 126.40 | 82,557 | 10,434,924 | 11,494,996 | 11.6 M to 11.5 M (-0.71 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 125.36 | 116,383 | 14,589,226 | 11,577,553 | 11.7 M to 11.6 M (-1.00 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 124.42 | 251,545 | 31,296,927 | 11,693,936 | 11.9 M to 11.7 M (-2.11 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 123.50 | 639,681 | 78,998,365 | 11,945,481 | 12.6 M to 11.9 M (-5.08 %) |
Mar 31 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 122.54 | 284,300 | 34,836,672 | 12,585,162 | 12.9 M to 12.6 M (-2.21 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 150.41 | 35,000 | 5,264,350 | 12,869,462 | 12.9 M to 12.9 M (-0.27 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 148.91 | 99,005 | 14,742,765 | 12,904,462 | 13 M to 12.9 M (-0.76 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 148.01 | 267,038 | 39,523,921 | 13,003,467 | 13.3 M to 13 M (-2.01 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 147.17 | 288,656 | 42,481,157 | 13,270,505 | 13.6 M to 13.3 M (-2.13 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 146.05 | 351,112 | 51,281,277 | 13,559,161 | 13.9 M to 13.6 M (-2.52 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 145.04 | 354,358 | 51,396,616 | 13,910,273 | 14.3 M to 13.9 M (-2.48 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 144.17 | 358,528 | 51,688,838 | 14,264,631 | 14.6 M to 14.3 M (-2.45 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 151.29 | 23,423 | 3,543,551 | 14,623,159 | 14.6 M to 14.6 M (-0.16 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 150.51 | 190,710 | 28,704,468 | 14,646,582 | 14.8 M to 14.6 M (-1.29 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 149.63 | 179,268 | 26,823,154 | 14,837,292 | 15 M to 14.8 M (-1.19 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 148.52 | 268,688 | 39,905,810 | 15,016,560 | 15.3 M to 15 M (-1.76 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 147.57 | 292,483 | 43,162,565 | 15,285,248 | 15.6 M to 15.3 M (-1.88 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 146.64 | 307,795 | 45,134,105 | 15,577,731 | 15.9 M to 15.6 M (-1.94 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 145.48 | 357,316 | 51,982,439 | 15,885,526 | 16.2 M to 15.9 M (-2.20 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 144.55 | 405,551 | 58,623,573 | 16,242,842 | 16.6 M to 16.2 M (-2.44 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 143.57 | 397,126 | 57,017,127 | 16,648,393 | 17 M to 16.6 M (-2.33 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 142.76 | 117,011 | 16,704,549 | 17,045,519 | 17.2 M to 17 M (-0.68 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 141.46 | 70,631 | 9,991,271 | 17,162,530 | 17.2 M to 17.2 M (-0.41 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 140.24 | 102,852 | 14,423,553 | 17,233,161 | 17.3 M to 17.2 M (-0.59 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 139.65 | 56,435 | 7,880,849 | 17,336,013 | 17.4 M to 17.3 M (-0.32 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 138.56 | 46,222 | 6,404,451 | 17,392,448 | 17.4 M to 17.4 M (-0.27 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 137.29 | 122,142 | 16,768,948 | 17,438,670 | 17.6 M to 17.4 M (-0.70 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 136.48 | 9,985 | 1,362,773 | 17,560,812 | 17.6 M to 17.6 M (-0.06 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 170.03 | 30,968 | 5,265,421 | 17,570,797 | 17.6 M to 17.6 M (-0.18 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 169.14 | 54,274 | 9,179,910 | 17,601,735 | 17.7 M to 17.6 M (-0.31 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 168.11 | 58,377 | 9,813,857 | 17,656,009 | 17.7 M to 17.7 M (-0.33 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 167.10 | 122,715 | 20,505,750 | 17,714,386 | 17.8 M to 17.7 M (-0.69 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 166.30 | 351,578 | 58,466,296 | 17,837,101 | 18.2 M to 17.8 M (-1.93 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 165.47 | 165,578 | 27,397,976 | 18,188,311 | 18.4 M to 18.2 M (-0.90 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 164.14 | 189,200 | 31,054,266 | 18,353,889 | 18.5 M to 18.4 M (-1.02 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 163.25 | 366,471 | 59,827,380 | 18,543,089 | 18.9 M to 18.5 M (-1.94 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 162.36 | 250,501 | 40,672,044 | 18,909,560 | 19.2 M to 18.9 M (-1.31 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 160.96 | 30,808 | 4,958,809 | 19,160,061 | 19.2 M to 19.2 M (-0.16 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 160.37 | 54,409 | 8,725,620 | 19,190,869 | 19.2 M to 19.2 M (-0.28 %) |
Feb 24 2021 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Sell | S | 159.18 | 161,887 | 25,769,076 | 19,245,278 | 19.4 M to 19.2 M (-0.83 %) |
May 26 2020 | RUBY | Rubius Therapeutic ... | AFEYAN NOUBAR | Director | Option Exercise | A | 6.22 | 25,000 | 155,500 | 25,000 | |
Apr 30 2020 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | A | 46.37 | 18,270 | 847,180 | 18,270 | |
Jun 28 2019 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | A | 14.34 | 54,660 | 783,824 | 54,660 | |
Jun 20 2019 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | P | 2.25 | 4,444,444 | 9,999,999 | 4,444,444 | 0 to 4.4 M |
Jun 20 2019 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | P | 2.25 | 4,444,444 | 9,999,999 | 4,444,444 | 0 to 4.4 M |
Jun 14 2019 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
Jun 13 2019 | EVLO | Evelo Biosciences, ... | AFEYAN NOUBAR | Director | Option Exercise | A | 7.07 | 15,690 | 110,928 | 15,690 | |
May 28 2019 | RUBY | Rubius Therapeutic ... | AFEYAN NOUBAR | Director | Option Exercise | A | 16.27 | 25,000 | 406,750 | 25,000 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 21,496 | 0 | 0 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 85,989 | 0 | 0 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 1,428,432 | 0 | 0 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 5,713,739 | 0 | 0 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 6,195,632 | 0 | 0 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 24,782,551 | 0 | 0 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 1,823,036 | 0 | 0 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 7,292,145 | 0 | 0 | |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 21,496 | 0 | 9,468,596 | 9.4 M to 9.5 M (+0.23 %) |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 85,989 | 0 | 37,874,424 | 37.8 M to 37.9 M (+0.23 %) |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 1,428,432 | 0 | 9,447,100 | 8 M to 9.4 M (+17.81 %) |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 5,713,739 | 0 | 37,788,435 | 32.1 M to 37.8 M (+17.81 %) |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 6,195,632 | 0 | 8,018,668 | 1.8 M to 8 M (+339.85 %) |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 24,782,551 | 0 | 32,074,696 | 7.3 M to 32.1 M (+339.85 %) |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 1,823,036 | 0 | 1,823,036 | 0 to 1.8 M |
Dec 13 2018 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 7,292,145 | 0 | 7,292,145 | 0 to 7.3 M |
Jul 18 2018 | RUBY | Rubius Therapeutic ... | AFEYAN NOUBAR | Director | Option Exercise | A | 23.00 | 25,000 | 575,000 | 25,000 | |
Jun 27 2018 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
Jun 27 2018 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
Jun 21 2017 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | A | 11.21 | 15,000 | 168,150 | 15,000 | |
May 27 2016 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Sell | J | 0.00 | 33,514 | 0 | 0 | 33.5 K to 0 (-100.00 %) |
May 27 2016 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | J | 0.00 | 7 | 0 | 33,514 | 33.5 K to 33.5 K (+0.02 %) |
May 27 2016 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | J | 0.00 | 33,507 | 0 | 33,514 | 7 to 33.5 K (+478,671.43 %) |
May 27 2016 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Sell | J | 0.00 | 200,000 | 0 | 1,925,462 | 2.1 M to 1.9 M (-9.41 %) |
May 27 2016 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Sell | J | 0.00 | 800,000 | 0 | 8,022,420 | 8.8 M to 8 M (-9.07 %) |
May 27 2016 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Sell | S | 27.60 | 599,297 | 16,540,597 | 0 | 599.3 K to 0 (-100.00 %) |
May 27 2016 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Sell | S | 27.60 | 80,141 | 2,211,892 | 1,925,462 | 2 M to 1.9 M (-4.00 %) |
May 27 2016 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Sell | S | 27.60 | 320,562 | 8,847,511 | 2,734,994 | 3.1 M to 2.7 M (-10.49 %) |
Dec 11 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 0.56 | 2,508 | 1,404 | 0 | 2.5 K to 0 (-100.00 %) |
Dec 11 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 0.56 | 43,930 | 24,601 | 0 | 43.9 K to 0 (-100.00 %) |
Nov 20 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | A | 0.52 | 5,000 | 2,600 | 5,000 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 508 | 71 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 254 | 36 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 254 | 36 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 254 | 36 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 254 | 36 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 3,256 | 456 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 32 | 73 | 58,232 | 58.3 K to 58.2 K (-0.05 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 508 | 71 | 58,264 | 57.8 K to 58.3 K (+0.88 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 16 | 36 | 57,756 | 57.8 K to 57.8 K (-0.03 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 254 | 36 | 57,772 | 57.5 K to 57.8 K (+0.44 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 16 | 36 | 57,518 | 57.5 K to 57.5 K (-0.03 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 254 | 36 | 57,534 | 57.3 K to 57.5 K (+0.44 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 16 | 36 | 57,280 | 57.3 K to 57.3 K (-0.03 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 254 | 36 | 57,296 | 57 K to 57.3 K (+0.45 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 16 | 36 | 57,042 | 57.1 K to 57 K (-0.03 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 254 | 36 | 57,058 | 56.8 K to 57.1 K (+0.45 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 206 | 468 | 56,804 | 57 K to 56.8 K (-0.36 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 3,256 | 456 | 57,010 | 53.8 K to 57 K (+6.06 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 8,410 | 1,177 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 4,205 | 589 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 4,205 | 589 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 4,205 | 589 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 4,205 | 589 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | X | 0.14 | 53,857 | 7,540 | 0 | |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 530 | 1,203 | 786,970 | 787.5 K to 787 K (-0.07 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 8,410 | 1,177 | 787,500 | 779.1 K to 787.5 K (+1.08 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 265 | 602 | 779,090 | 779.4 K to 779.1 K (-0.03 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 4,205 | 589 | 779,355 | 775.2 K to 779.4 K (+0.54 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 265 | 602 | 775,150 | 775.4 K to 775.2 K (-0.03 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 4,205 | 589 | 775,415 | 771.2 K to 775.4 K (+0.55 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 265 | 602 | 771,210 | 771.5 K to 771.2 K (-0.03 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 4,205 | 589 | 771,475 | 767.3 K to 771.5 K (+0.55 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 265 | 602 | 767,270 | 767.5 K to 767.3 K (-0.03 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 4,205 | 589 | 767,535 | 763.3 K to 767.5 K (+0.55 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Sell | S | 2.27 | 3,390 | 7,695 | 763,330 | 766.7 K to 763.3 K (-0.44 %) |
Jul 29 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Buy | X | 0.14 | 53,857 | 7,540 | 766,720 | 712.9 K to 766.7 K (+7.56 %) |
Jul 16 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | P | 0.00 | 397,072 | 0 | 497,729 | |
Jul 16 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 100,657 | 0 | 100,657 | |
Jul 16 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | P | 0.00 | 53,465 | 0 | 67,018 | |
Jul 16 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 13,553 | 0 | 13,553 | |
Jul 16 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | P | 0.00 | 725,725 | 0 | 909,696 | |
Jul 16 2015 | BGMD | BG Medicine, Inc. | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 183,971 | 0 | 183,971 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | A | 18.00 | 15,000 | 270,000 | 15,000 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 454,546 | 0 | 0 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 1,818,181 | 0 | 0 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 224,719 | 0 | 0 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 898,877 | 0 | 0 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 599,297 | 0 | 0 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 1,526,338 | 0 | 0 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | C | 0.00 | 6,105,362 | 0 | 0 | |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 599,297 | 0 | 599,297 | 0 to 599.3 K |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 2,205,603 | 0 | 2,205,603 | 0 to 2.2 M |
Jun 29 2015 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | C | 0.00 | 8,822,420 | 0 | 8,822,420 | 0 to 8.8 M |
Apr 03 2007 | AGEN | AGENUS INC | AFEYAN NOUBAR | Director | Option Exercise | A | 0.00 | 5,379 | 0 | 255,275 | |
Jan 04 2007 | AGEN | AGENUS INC | AFEYAN NOUBAR | Director | Option Exercise | A | 0.00 | 3,492 | 0 | 248,149 | |
Dec 15 2006 | AGEN | AGENUS INC | AFEYAN NOUBAR | Director | Sell | S | 1.95 | 5,000 | 9,759 | 0 | 5 K to 0 (-100.00 %) |
Oct 05 2006 | AGEN | AGENUS INC | AFEYAN NOUBAR | Director | Option Exercise | A | 0.00 | 4,043 | 0 | 244,657 |